Kintor Pharmaceutical Company Description

Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology in the People’s Republic of China.

Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia (AGA) and acne vulgaris, which is in phase III clinical trial; and GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris that is in phase II clinical trial.

The company is developing GT1708F (Hedgehog/SMO Inhibitor), an inhibitor of the hedgehog signal transduction pathway to treat idiopathic pulmonary fibrosis, and blood cancer; GT0486, an inhibitor of the PI3K/mTOR signalling pathway and a second generation mTOR inhibitor for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and hepatocellular carcinoma (HCC); and ALK-1 Antibody (GT90001), an anti-angiogenesis inhibitor and targets a new biological target activin receptor-like kinase-1 globally to treat metastatic hepatocellular carcinoma, a common type of liver cancer, and a variety of solid tumours.

Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People’s Republic of China.

Kintor Pharmaceutical Limited

Country	Cayman Islands
Founded	2009
Industry	Biotechnology
Sector	Healthcare
Employees	168
CEO	Youzhi Tong

Contact Details

Address: Suzhou Industrial Park Suzhou, 215123 China
Phone	86 51 2626 39909
Website	kintor.com.cn

Stock Details

Ticker Symbol	9939
Exchange	Hong Kong Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	KYG5273B1077
SIC Code	2836

Key Executives

Name	Position
Dr. Youzhi Tong	Founder, Chief Executive Officer and Executive Chairman
Dr. Xiang Ni	Chief Medical Officer and Executive Director
Ming Ming Cheung	Joint Company Secretary and Chief Financial Officer
Wai Chiu Wong C.P.A., CTP, FCS	Company Secretary